Houston-based Bellicum Pharmaceuticals Inc. (Nasdaq: BLCM), a clinical-stage biopharmaceutical company focused on cellular immunotherapies, is selling a local facility to the University of Texas M.D. Anderson Cancer Center. M.D. Anderson will pay $15 million for the 60,000-square-foot facility, including manufacturing, office and laboratory space, according to a press release. Approximately 35 employees at the facility will transfer to M.D.